Opendata, web and dolomites

Curtana

Patented small molecule therapeutics that target cancer stem cells for the treatment of glioblastoma and other brain cancers

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Curtana project word cloud

Explore the words cloud of the Curtana project. It provides you a very rough idea of what is the project "Curtana" about.

kills    indicate    ct    nervous    improvement    small    deadliest    bulk    drug    clinical    potent    standard    hope    gliomas    treatment    rates    drugs    curtana    little    tumours    olig2    identification    benefit    ineffective    tumorigenesis    cytotoxic    cure    malignant    feasibility    answer    barrier    14    progression    ovarian    centre    people    therapies    primary    months    reduce    80    central    endometrial    cells    tumour    molecule    investors    crosses    expressed    index    aggressive    care    conventional    survival    diagnoses    found    rate    most    transcription    drive    therapeutic    orally    marketing    179    68    biggest    glioblastoma    accounting    compound    45    instrumental    radiosensitiser    lung    expansion    13    killer    trials    offers    stem       patients    brain    over    relative    killing    255    bioavailable    tolerated    worldwide    die    cancer    inhibiting    diagnosed    approval    median    too    blood    cancers   

Project "Curtana" data sheet

The following table provides information about the project.

Coordinator
CURTANA PHARMA LTD 

Organization address
address: 72 GREAT SUFFOLK STREET
city: LONDON
postcode: SE1 0BL
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website http://www.curtanapharma.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-02-01   to  2017-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CURTANA PHARMA LTD UK (LONDON) coordinator 50˙000.00

Map

 Project objective

Over 45,000 people die each year in Europe – and 255,000 worldwide – from cancers of the brain and central nervous system. Gliomas are the biggest killer, accounting for a third of all diagnoses and 80% of primary malignant brain tumours. Among these glioblastoma is the most common, most aggressive and deadliest. Standard of care treatment offers little hope for patients diagnosed with gliomas: there is no cure, the median survival is 14.6 months and the 2-year survival rate is 13.5%. Conventional therapies can reduce tumour bulk, but they are ineffective at killing the cancer stem cells that drive tumour progression. Curtana may have found the answer. Its novel approach targets a transcription factor, Olig2, which is instrumental in tumorigenesis, tumour expansion and survival. By inhibiting Olig2, Curtana’s small molecule compound, CT-179, kills cancer stem cells. Pre-clinical results show CT-179 to be cytotoxic in selected tumours, a potent radiosensitiser, orally bioavailable and well tolerated; it also crosses the blood-brain barrier and has a high therapeutic index relative to conventional cancer drugs. Most importantly, it increases survival rates (in early studies, median improvement was 68%). Results indicate it may have benefit for other cancers too – any in which Olig2 is highly expressed, including all gliomas and other cancers such as lung, ovarian and endometrial. The Phase 1 project will address the feasibility of carrying out the further pre-clinical and clinical studies required before Curtana can apply for drug marketing approval. This will include identification of clinical partners for multi-centre trials that would be carried out in Europe in Phase 2, as well as potential investors.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CURTANA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CURTANA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More